BioSpace News Archive

The Laboratory for Genomics Research will be funded by GSK up to $67 million over the five-year period and will include space for 24 full-time university employees and up to 14 full-time GSK staffers.

Biotech and pharma companies strengthen their leadership teams and boards with new hires and appointments.

A substantial number of blood cancer patients could make more informed decisions on their treatment if more information becomes available for them and their treating physicians.

Virtue® SEB is expected to become a flagship therapeutic product for Terumo and will strengthen its broad US and global portfolio of interventional solutions

Bioz, Inc., a Silicon Valley AI data company, is proud to announce a new partnership with the world leader in the discovery and production of enzymes for molecular biology applications: New England Biolabs®.

AbCellera will use its technology to look for ultra-rare antibodies with specific properties defined by Gilead.

The pilot program aims to develop an electronic system to identify and trace certain prescription drugs as they are distributed within the United States.

Lifestyle-related diseases, an ageing population and rapid technical progress all mean that major investments need to be made in the life science sector over the next few years. Semcon is now increasing the pace of its growth in this field.

Pyoderma Gangraenosum is a debilitating, rare autoimmune disease marked by large, painful skin ulcers

Amarantus Bioscience Holdings, Inc. announced that subsidiary MANF Therapeutics was issued U.S. Patent No. 10,195,251 entitled ‘Methods of Treatment for Retinal Diseases Using MANF and CDNF’ that covers the use of mesencephalic astrocyte-derived neurotrophic factor or cerebral dopamine neurotrophic factor as a treatment for various ophthalmic disorders, including inherited retinal disorders, age-related macular degeneration and glaucoma.